共 50 条
- [1] Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Tawbi, Hussein Abdul-HassanPeng, WeiyiPhillips, SuzanneMilton, Denai R.Amaria, Rodabe NavrozeDiab, AdiGlitza, Isabella ClaudiaPatel, Sapna PradyumanWong, Michael K. K.Yee, CassianMcQuade, Jennifer LeighTetzlaff, Michael T.Lazar, Alexander J.Shephard, MichaelCain, SuzanneBurton, Elizabeth M.Hwu, PatrickDavies, Michael A.
- [2] Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Dumbrava, Ecaterina ElenaBurton, Elizabeth M.Subudhi, Sumit KumarMilton, Denai R.Aparicio, AnaYap, Timothy A.Naing, AungCorn, Paul GettysPilie, Patrick GlenZurita, Amado J.Wang, JenniferAmaria, Rodabe NavrozeMcQuade, Jennifer LeighGlitza, Isabella ClaudiaLazar, Alexander J.Meric-Bernstam, FundaLogothetis, ChristopherDavies, Michael A.Hwu, PatrickTawbi, Hussein A.
- [3] Ph I/II study of PI3K-b inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumorsANNALS OF ONCOLOGY, 2021, 32 : S899 - S899Burton, E.Dumbrava, E. E. IleanaPeng, W.Milton, D.Amaria, R.Mcquade, J.Glitza, I. C.Hong, D.Patel, S.Rodon, J.Yap, T. A.Naing, A.Piha-Paul, S. A.Balmes, G.Lazar, A.Meric-Bernstam, F.Hwu, P.Davies, M. A.Tawbi, H. A.
- [4] NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/ del) or PTEN protein lossANNALS OF ONCOLOGY, 2018, 29 : 137 - 137Janku, F.Jegede, O.Puhalla, S. L.Konstantinopoulos, P.Meric-Bernstam, F.Mitchell, E. P.Zwiebel, J. A.McShane, L. M.Li, S.Rubinstein, L. V.Doyle, L. A.Patton, D.Conley, B. A.O'Dwyer, P. J.Harris, L. N.Arteaga, C.Williams, P. M.Hamilton, S. R.Chen, A. P.Flaherty, K. T.
- [5] A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerCLINICAL CANCER RESEARCH, 2021, 27 (19) : 5248 - 5257Sarker, DebashisDawson, Nancy A.Aparicio, Ana M.Dorff, Tanya B.Pantuck, Allan J.Vaishampayan, Ulka N.Henson, LynnVasist, LakshmiRoy-Ghanta, SumitaGorczyca, MicheleYork, WhitneyGanji, GopinathTolson, Jerryde Bono, Johann S.
- [6] Exploratory genetic analysis of tumors from a phase I/II dose escalation study of GSK2636771 in patients (pts) with PTEN deficient advanced tumorsCANCER RESEARCH, 2015, 75de Bono, JohannArkenau, Hendrik-TobiasMateo, JoaquinInfante, Jeffrey R.Burris, Howard A.Bang, Yung-JueEder, JosephSharma, SunilChung, Hyun C.Decordova, ShaunSwales, Karen E.Garrett, Michelle D.Roda-Perezi, DesamaparadosDing, MeichunRusso, MarkYang, LiSuttle, BenTolson, Jerry M.Halsey, Wendy S.Gopi, GanjiVan Der Keyl, Harjeet K.Kalyana-Sundaram, ShankerSathe, Ganesh M.Motwani, MonicaKumar, Rakesh
- [7] A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumorsJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Arkenau, Hendrik-TobiasMateo, JoaquinLemech, Charlotte RoseInfante, Jeffrey R.Burris, Howard A.Bang, Yung-JueEder, Joseph PaulHerbst, Roy S.Sharma, SunilChung, Hyun CheolDecordova, ShaunSwales, Karen E.Garrett, Michelle D.Loftiss, Jill I.Durante, MichaelRusso, Mark W.Suttle, Benjamin B.Motwani, MonicaKumar, RakeshDe Bono, Johann Sebastian
- [8] An open-label, multi-centre, phase Ib/II study of PI3Kβ selective inhibitor GSK2636771 administered in combination with paclitaxel in patients with advanced gastric cancer having alterations in PI3K/Akt pathwayANNALS OF ONCOLOGY, 2021, 32 : S206 - S206Jung, M.Kim, C.Kim, H.Lee, C.Lee, H.Bae, W.Jeung, H.Zang, D.Park, S.Hwang, I.Kim, H.Rha, S.Chung, H.
- [9] Phase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K)β inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC)ANNALS OF ONCOLOGY, 2017, 28Rescigno, P.de Bono, J.Aparicio, A.Chowdhury, S.Twardowski, P.Dawson, N.Vaishampayan, U.Pantuck, A. J.Zhou, Y.Fecteau, D.Ganji, G.Tolson, J.Smith, D. A.Medina, J.Yan, L.
- [10] A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Burton, Elizabeth M.Woody, TimothyGlitza, Isabella ClaudiaAmaria, Rodabe NavrozeKeung, Emily Zhi-YunDiab, AdiPatel, Sapna PradyumanWong, Michael K. K.Yee, CassianHwu, PatrickMcQuade, Jennifer LeighWoodman, Scott EricTetzlaff, Michael T.Davies, Michael A.Wargo, Jennifer AnnRai, KunalTawbi, Hussein Abdul-Hassan